摘要
目的:探讨C-erbB-2、表皮生长因子受体(EGFR)和nm23-H1在膀胱癌中的表达及临床意义。方法:应用免疫组织化学S-P法检测69例膀胱癌和12例正常膀胱黏膜中C-erbB-2,EGFR和nm23-H1的表达情况。结果:C-erbB-2,EGFR和nm23-H1在膀胱癌中的阳性表达率分别是44.9%,56.5%和60.9%,在正常膀胱黏膜中的阳性表达率分别为0.00%,0.00%和100%,两两比较差异均有显著性(P<0.01),其中C-erbB-2和EGFR的阳性表达率随着膀胱癌病理分级和临床分期的增高而增高,nm23-H1的阳性表达率随着膀胱癌病理分级和临床分期的增高而降低。结论:C-erbB-2,EGFR和nm23-H1的异常表达在膀胱癌的发生及发展过程中起着重要作用。
Objective：To study the expression of c-erbB-2,EGFR and nm23-H1 and its clinical significance in Human Bladder.Methods：We study the expression of c-erbB-2,EGFR and nm23-H1 in 69 cases of human bladder cancer and 12 cases of normal bladder mucosa by immunohistochemical technique SP procedure.Results：The positive expres-sion rates of C-erbB-2,EGFR and nm23-H1 are 44.9%,56.5% and 62.3% in bladder cancer,and are respectively 0.0%,0.0% and 100.0%in normal bladder mucosa,their expression rates show distinct defferent between normal bladder mucosa and blander cancer（P0.01）.With the increasing of pathological grade and clinical stage of bladder cancer,the positive expression rates of C-erbB-2 and EGFR increased,however,the positive expression rate of nm23-H1 decreased.Conclusion：The abnormal expression of C-erbB-2,EGFR and nm23-H1 plays an important part in the genesis and development of human bladder cancer.
出处
《临床医药实践》
2011年第5期333-336,共4页
Proceeding of Clinical Medicine
